SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

This is a randomized, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of SYS6010 versus docetaxel in participants with Locally Advanced or Metastatic EGFR Wild-type Non-squamous Non-small Cell Lung Cancer who Have Failed Standard Therapy. The primary Objective is to evaluate the efficacy of SYS6010 versus docetaxel in participants with EGFR wild-type locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC). Secondary Objectives includes safety, quality of life, immunogenicity, biomarkers, and efficacy correlations of SYS6010 compared to docetaxel in the same patient population.

NCT Number	NCT07442565
Lead Sponsor	CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions	Non-Small Cell Lung Cancer
Enrollment	506 participants
Start Date	2026-03-10
Primary Completion	2027-12-30 (estimated)
Study Completion	2031-05-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-04